PCA3 and prostate carcinoma: Currently, PCA3 is also an auxiliary biomarker in prostate cancer; its use was approved by the Food and Drug Administration (FDA) in 2012 [44] due to its clinical utility by reducing the number of unnecessary biopsies in patients.